Inhibikase Therapeutics, Inc. (IKT)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q1-2026 | 8-K (2026-05-12) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-26) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-14) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-14) · 99.1 · 99.2 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-14) · 99.1 | ||
| 10-K/A | FY-2024 | |||
| 10-K | FY-2024 | 8-K (2025-03-27) · 99.1 | ||
| 10-Q | Q3-2024 | — | ||
| 10-Q | Q2-2024 | — | ||
| 10-Q | Q1-2024 | — | ||
| 10-K | FY-2023 | — | ||
| 10-Q | Q3-2023 | — | ||
| 10-K/A | FY-2022 | |||
| 10-Q | Q2-2023 | — |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Condensed Balance Sheets | — |
|
| Consolidated Balance Sheets | ||
| Condensed Balance Sheets (P) | — |
|
| Consolidated Balance Sheets (P) | ||
| Condensed Statements of Operations (unaudited) | — |
|
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Condensed Statements of Stockholders' Equity (unaudited) | — |
|
| Consolidated Statements of Stockholders' Equity | ||
| Consolidated Statements of Stockholders' Equity (deficit) | — |
|
| Condensed Statements of Cash Flows (unaudited) | — |
|
| Consolidated Statements of Cash Flows | ||
| Notes | ||
| Abli License Agreement | ||
| Acquisition of Corhepta | ||
| Atm Program | ||
| Atm Program/open Market Sales Agreement | — |
|
| Award Timing Disclosure | — |
|
| Basis of Presentation and Significant Accounting Policies | — |
|
| Commitments and Contingencies | ||
| Correction of Prior Period Immaterial Error | — |
|
| Cybersecurity Risk Management, Strategy, and Governance | — |
|
| Equipment and Improvements | ||
| Fair Value of Financial Instruments | ||
| Going Concern | — |
|
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Insurance Premium Financing Payable | — |
|
| Liquidity | — |
|
| Marketable Securities | ||
| Nature of Business | ||
| Net Loss Per Share | ||
| Pay Vs Performance Disclosure | ||
| Segment Information | ||
| Simple Retirement Account For Employees (the "simple Ira") | — |
|
| Stock-based Compensation | ||
| Stockholders' Equity | ||
| Stockholders' Equity (deficit) | — |
|
| Subsequent Events | ||
| Summary of Significant Accounting Policies | — |
|
| Supplemental Balance Sheet Information | ||
| Supplemental Condensed Consolidated Balance Sheet Information | — |
|
| Warrants | ||